Archives
-
6-FAM SE: Identity, Mechanism and Evidence Limits
2026-10-19
6-FAM SE is a supplier-described amine-reactive fluorescent labeling reagent for DNA, proteins, peptides and nucleotides. The available evidence supports its chemical identity and conceptual use, but not assay-specific performance or comparative claims.
-
DAPI Solution: Identity, Mechanism, and Evidence Limits
2026-10-19
APExBIO’s DAPI Solution (1 mg/mL; SKU K2401) is described as a DMSO-based stock of 4',6-Diamidino-2-Phenylindole, a blue-fluorescent DNA-binding stain for nuclear visualization and membrane-accessibility-associated readouts. The documented information supports a measurement role in microscopy and flow cytometry, but no identity-matched research paper, comparative dataset, or product-specific outcome statistics are available to establish performance or disease-specific interpretation.
-
Toremifene: Product Record and Evidence Boundaries
2026-10-18
The APExBIO product record identifies Toremifene, SKU A3884, as a second-generation selective estrogen-receptor modulator and reports an approximately 1 ± 0.3 μM IC50 for inhibition of cell growth in Ac-1 cells. It also describes prior in vitro, in vivo, and atamestane-combination xenograft work, but provides no identity-matched paper, sample sizes, assay endpoint definitions, comparator details, or independent validation. The evidence therefore supports a bounded overview of product identity, estrogen-receptor modulation, and measurement interpretation—not a complete efficacy or mechanism claim.
-
Pivanex (AN-9): Evidence and Mechanism Scope
2026-10-17
Pivanex (AN-9) is identified by APExBIO as the synthetic butyric-acid derivative pivalyloxymethyl butyrate, with reported apoptosis-promoting, anti-metastatic and anti-angiogenic activity. Because no identity-matched research paper or outcome dataset is available here, these claims should be treated as supplier-described research context rather than independently established mechanism or efficacy.
-
FPH1 (BRD-6125): Evidence and Scope
2026-10-16
FPH1, also called BRD-6125, is described by APExBIO as a phenotypic small molecule associated with hepatocyte proliferation and selected functional readouts. The available product information reports changes in nuclei count, mitotic activity, albumin secretion, CYP3A4, and AFP, but provides no matched peer-reviewed study, quantitative effect sizes, sample sizes, uncertainty estimates, molecular target, or independent replication. Its current evidentiary scope is therefore that of a supplier-described research tool rather than an established mechanistic or clinical hepatocyte-expansion agent.
-
Berbamine Hydrochloride: Evidence and Scope
2026-10-16
APExBIO describes Berbamine hydrochloride as a plant-derived isoquinoline alkaloid salt associated with STAT3 modulation, disruption of intracellular calcium homeostasis, and reported cytotoxicity in KU812 and HepG2 cell contexts. Because no identity-matched research paper is available, these claims remain catalog-reported observations rather than independently verified mechanisms or comparative efficacy evidence.
-
What EPI-001 Evidence Shows in TNBC
2026-10-15
Published evidence links AR and ARv7 with adverse features in selected triple-negative breast cancer cohorts and reports that EPI-001 altered metastasis- and EMT-associated readouts in one TNBC cell model. The findings support a mechanistic hypothesis, but they do not establish clinical efficacy, causal prognostic value, superiority over enzalutamide, or supplier-specific product performance.
-
Ac-YVAD-CMK: What the Product Record Supports
2026-10-15
APExBIO identifies Ac-YVAD-CMK, also called N-Ac-Tyr-Val-Ala-Asp-CMK, as a selective and irreversible caspase-1 inhibitor. Its documented conceptual scope is the study of caspase-1-dependent inflammatory signaling, including maturation and release of IL-1β and IL-18 and pyroptosis-associated responses. However, the available product information is not a matched research study: it supplies no independent validation, effect sizes, sample sizes, assay results, or evidence that the compound performed as described in a particular model.
-
Caspase-9 Evidence in Graphene FIR Melanoma Research
2026-10-14
A 2025 BMC Cancer study used Z-LEHD-FMK alongside Z-DEVD-FMK to test whether graphene-associated far-infrared radiation induced melanoma-cell death through caspase-9- and caspase-3-linked apoptosis. The inhibitor-rescue findings support involvement of this pathway, but they do not by themselves establish that mitochondrial caspase-9 activation was the initiating event or that a particular commercial Z-LEHD-FMK formulation was used.
-
Mouse Tissue Lysis Kit K1038: Evidence Overview
2026-10-14
The Mouse Tissue Lysis Kit (K1038), supplied by APExBIO, is documented as a research-use sample-lysis product intended to support direct genotyping workflows. The available evidence is limited to supplier-provided product information; no matched peer-reviewed paper or independent performance study was identified.
-
Biotin Detection and BmTyr Proximity Labeling
2026-10-13
Streptavidin-HyperFluor™ 647 is a supplier-described red/far-red fluorescent streptavidin conjugate for detecting biotinylated targets. The supplied 2026 BmTyr study describes a conceptually different, biotin-free proximity-labeling platform based on alkyne–azide chemistry in primary T cells. These approaches address related imaging and proteomic questions but should not be treated as interchangeable. Evidence for the BmTyr platform is limited to the reported study and its stated biological context, while product performance claims are sourced from the supplier description rather than an independent comparative evaluation.
-
TSPAN18–STIM1 and Prostate Cancer Bone Metastasis
2026-10-13
Zhou et al. describe a mechanistic link between TSPAN18, STIM1 stability, calcium signaling, and prostate cancer bone metastasis. The study supports TSPAN18 as a candidate regulator, but it does not establish Toremifene as an intervention or demonstrate clinical therapeutic benefit.
-
EPI-001 and ARv7: Evidence Gaps in TNBC
2026-10-12
A source-grounded assessment of reported EPI-001 and enzalutamide comparisons in triple-negative breast cancer, distinguishing prognostic associations from mechanistic evidence and identifying limits on interpretation.
-
Toremifene and Prostate Cancer Research: Evidence Boundaries
2026-10-12
The supplied evidence describes Toremifene as a selective estrogen-receptor modulator with reported activity in selected prostate cancer research models, while Zhou et al. investigate a separate TSPAN18–STIM1–TRIM32 mechanism in bone metastasis. The available sources do not establish that Toremifene acts on this calcium-signaling axis or that supplier-reported assay results translate to clinical benefit.
-
Fulvestrant: A Causal Lens on ER Signaling
2026-10-10
Fulvestrant (ICI 182,780) is best understood not only as an ER antagonist, but also as a causal probe for distinguishing receptor-dependent signaling from downstream stress responses. This article connects breast cancer findings on MDM2 protein degradation with immune-endocrine evidence while defining the limits of cross-model interpretation.